Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 341654, 7 pages
Research Article

FOXP3 Transcription Factor: A Candidate Marker for Susceptibility and Prognosis in Triple Negative Breast Cancer

1Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Science Center, State University of Londrina, 86057-970 Londrina, PR, Brazil
2Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, State University of Londrina, 86057-970 Londrina, PR, Brazil
3Department of Medical Clinic, Health Sciences Center, State University of Londrina, 86057-970 Londrina, PR, Brazil
4Department of Basic Health Sciences, Maringá State University, 87020-900 Maringá, PR, Brazil

Received 20 February 2014; Accepted 9 April 2014; Published 30 April 2014

Academic Editor: Rutao Cui

Copyright © 2014 Leandra Fiori Lopes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Triple negative breast cancer (TNBC) is a relevant subgroup of neoplasia which presents negative phenotype of estrogen and progesterone receptors and has no overexpression of the human epidermal growth factor 2 (HER2). FOXP3 (forkhead transcription factor 3) is a marker of regulatory T cells (Tregs), whose expression may be increased in tumor cells. This study aimed to investigate a polymorphism (rs3761548) and the protein expression of FOXP3 for a possible involvement in TNBC susceptibility and prognosis. Genetic polymorphism was evaluated in 50 patients and in 115 controls by allele-specific PCR (polymerase chain reaction). Protein expression was evaluated in 38 patients by immunohistochemistry. It was observed a positive association for homozygous AA (OR = 3.78; 95% CI = 1.02–14.06) in relation to TNBC susceptibility. Most of the patients (83%) showed a strong staining for FOXP3 protein in the tumor cells. In relation to FOXP3-positive infiltrate, 47% and 58% of patients had a moderate or intense intratumoral and peritumoral mononuclear infiltrate cells, respectively. Tumor size was positively correlated to intratumoral FOXP3-positive infiltrate ( ). In conclusion, since FOXP3 was positively associated with TNBC susceptibility and prognosis, it seems to be a promising candidate for further investigation in larger TNBC samples.